丹纳赫西部创新中心落户重庆两江新区_老虎社区_美港股上老虎

丹纳赫西部创新中心落户重庆两江新区

新浪财经04-01

转自：中国证券网上证报中国证券网讯 3月31日，丹纳赫与重庆两江新区管理委员会签署战略合作协议，双方将共建丹纳赫西部创新中心项目，服务成渝地区医药科研与创新转化。据悉，作为该项目一部分，丹纳赫还将在此设立生命科学研究院。这是继上海、广州之后，丹纳赫生命科学平台在国内设立的第三处研究院，服务生物药和精准医学的前沿应用方法开发。同时，丹纳赫旗下Cytiva（思拓凡）还将设立思拓凡西部科创中心，开展...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2424674590?lang=zh_CN&edition=full","thumbnail":"http://n.sinaimg.cn/default/feedbackpics/transform/116/w550h366/20180418/fw0w-fzihnep5208648.png","is_english":false,"pubTime":"2024-04-01 22:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2424674590","market":"us","top_or_hot":-1,"title":"丹纳赫西部创新中心落户重庆两江新区","media":"新浪财经","content":"<div>\n<p>转自：中国证券网\n上证报中国证券网讯 3月31日，丹纳赫与重庆两江新区管理委员会签署战略合作协议，双方将共建丹纳赫西部创新中心项目，服务成渝地区医药科研与创新转化。\n据悉，作为该项目一部分，丹纳赫还将在此设立生命科学研究院。这是继上海、广州之后，丹纳赫生命科学平台在国内设立的第三处研究院，服务生物药和精准医学的前沿应用方法开发。同时，丹纳赫旗下Cytiva（思拓凡）还将设立思拓凡西部科创中心，开展...</p>\n\n<a href=\"https://city.sina.com.cn/city_finance/2024-04-01/detail-inaqiert7147159.shtml\">网页链接</a>\n\n</div>\n","source":"sina_us","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>丹纳赫西部创新中心落户重庆两江新区</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n丹纳赫西部创新中心落户重庆两江新区\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-01 22:29 北京时间&nbsp;&nbsp;&nbsp;<a href=https://city.sina.com.cn/city_finance/2024-04-01/detail-inaqiert7147159.shtml><strong>新浪财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>转自：中国证券网\n上证报中国证券网讯 3月31日，丹纳赫与重庆两江新区管理委员会签署战略合作协议，双方将共建丹纳赫西部创新中心项目，服务成渝地区医药科研与创新转化。\n据悉，作为该项目一部分，丹纳赫还将在此设立生命科学研究院。这是继上海、广州之后，丹纳赫生命科学平台在国内设立的第三处研究院，服务生物药和精准医学的前沿应用方法开发。同时，丹纳赫旗下Cytiva（思拓凡）还将设立思拓凡西部科创中心，开展...</p>\n\n<a href=\"https://city.sina.com.cn/city_finance/2024-04-01/detail-inaqiert7147159.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2106854487.HKD","symbol_name":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","start_time":0,"source_url":"https://city.sina.com.cn/city_finance/2024-04-01/detail-inaqiert7147159.shtml","article_id":"2424674590","we_media_id":null,"thumbnails":["http://n.sinaimg.cn/default/feedbackpics/transform/116/w550h366/20180418/fw0w-fzihnep5208648.png"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2424674590","pubTimestamp":1711981750,"sourceInfo":{"source_id":"sina_us","name":"新浪美股"},"weMediaInfo":null,"summary":"上证报中国证券网讯 3月31日，丹纳赫与重庆两江新区管理委员会签署战略合作协议，双方将共建丹纳赫西部创新中心项目，服务成渝地区医药科研与创新转化。据悉，作为该项目一部分，丹纳赫还将在此设立生命科学研究院。公司介绍称，丹纳赫西部创新中心是重庆两江新区引入的首个世界500强跨国医药企业项目。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","BK4585":"ETF&股票定投概念","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4534":"瑞士信贷持仓","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","LU2125910179.SGD":"Natixis Thematics Water H-R/A SGD","LU2063271972.USD":"富兰克林创新领域基金","DHR":"丹纳赫","LU2125910336.SGD":"Natixis Thematics Water R/A SGD","BK4588":"碎股","LU0175139822.USD":"AB FCP I Global Equity Blend A USD","LU0097036916.USD":"贝莱德美国增长A2 USD","LU1923621640.USD":"Natixis Thematics Water R/A USD","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0122379950.USD":"贝莱德世界健康科学A2","LU0289960550.SGD":"AB FCP I - GLOBAL EQUITY BLEND PORTFOLIO 'A' (SGD) ACC","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","BK4581":"高盛持仓","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","SG9999001176.USD":"United Global Healthcare Acc USD","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0109391861.USD":"富兰克林美国机遇基金A Acc","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD"},"translate_title":"Danahe Western Innovation Center settled in Liangjiang New District, Chongqing","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DHR":1},"content_text":"转自：中国证券网\n上证报中国证券网讯 3月31日，丹纳赫与重庆两江新区管理委员会签署战略合作协议，双方将共建丹纳赫西部创新中心项目，服务成渝地区医药科研与创新转化。\n据悉，作为该项目一部分，丹纳赫还将在此设立生命科学研究院。这是继上海、广州之后，丹纳赫生命科学平台在国内设立的第三处研究院，服务生物药和精准医学的前沿应用方法开发。同时，丹纳赫旗下Cytiva（思拓凡）还将设立思拓凡西部科创中心，开展生物医药工艺技术开发、人才培训、项目孵化转化和卫生经济学评估等。\n公司介绍称，丹纳赫西部创新中心是重庆两江新区引入的首个世界500强跨国医药企业项目。当前，两江新区正把生命健康产业作为支柱产业，按照“一城两园两中心”发展思路，加快打造医疗器械、生物制品、化学制剂三大标志性产业集群，以及新中药、新服务、新医疗三大新兴产业。（何昕怡）\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}